Germany · Delayed Price · Currency is EUR 4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of EUR 128.78 million. The enterprise value is 116.53 million.
| Market Cap | 128.78M |
| Enterprise Value | 116.53M |
Important Dates
The next estimated earnings date is Thursday, May 21, 2026.
| Earnings Date | May 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 15.48M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.92% |
| Shares Change (QoQ) | +14.52% |
| Owned by Insiders (%) | 14.70% |
| Owned by Institutions (%) | 40.62% |
| Float | 5.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.05 |
| PB Ratio | 5.82 |
| P/TBV Ratio | 6.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.93 |
| EV / Sales | 57.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.84 |
Financial Position
The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.81.
| Current Ratio | 11.36 |
| Quick Ratio | 10.38 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.06 |
| Interest Coverage | -18.58 |
Financial Efficiency
Return on equity (ROE) is -209.34% and return on invested capital (ROIC) is -42.88%.
| Return on Equity (ROE) | -209.34% |
| Return on Assets (ROA) | -39.27% |
| Return on Invested Capital (ROIC) | -42.88% |
| Return on Capital Employed (ROCE) | -44.64% |
| Revenue Per Employee | 18,867 |
| Profits Per Employee | -152,814 |
| Employee Count | 110 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -379,144 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 9.02 |
| 200-Day Moving Average | 11.74 |
| Relative Strength Index (RSI) | 37.80 |
| Average Volume (20 Days) | 58 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of EUR 2.08 million and -16.81 million in losses. Loss per share was -1.16.
| Revenue | 2.08M |
| Gross Profit | 1.28M |
| Operating Income | -17.89M |
| Pretax Income | -17.19M |
| Net Income | -16.81M |
| EBITDA | -17.15M |
| EBIT | -17.89M |
| Loss Per Share | -1.16 |
Balance Sheet
The company has 30.46 million in cash and 18.01 million in debt, giving a net cash position of 12.45 million.
| Cash & Cash Equivalents | 30.46M |
| Total Debt | 18.01M |
| Net Cash | 12.45M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 22.15M |
| Book Value Per Share | 1.43 |
| Working Capital | 30.54M |
Cash Flow
In the last 12 months, operating cash flow was -16.06 million and capital expenditures -969,443, giving a free cash flow of -17.03 million.
| Operating Cash Flow | -16.06M |
| Capital Expenditures | -969,443 |
| Free Cash Flow | -17.03M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 61.55% |
| Operating Margin | -861.83% |
| Pretax Margin | -828.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.92% |
| Shareholder Yield | -15.92% |
| Earnings Yield | -13.05% |
| FCF Yield | -13.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4basebio has an Altman Z-Score of 3.22 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.22 |
| Piotroski F-Score | 3 |